Earnings ·
Adicet Bio reports Q3 net loss of $18.9M, or $1.76 per share
ACETAdicet Bio, Inc.
Adicet Bio reported a net loss of $18.9 million for the third quarter ended September 30, 2026, equating to a loss of $1.76 per basic and diluted share. Research and development expenses decreased to $15.6 million from $22.9 million in the prior-year period, while general and administrative costs fell to $4.2 million from $5.1 million. The company held $100.9 million in cash, cash equivalents, and short-term investments as of September 30, 2026, which management expects will fund operations into the second half of 2027. Adicet Bio is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies, and solid tumors.